AsianScientist (Sep. 23, 2013) – Stratpharma AG and Luqa Pharmaceuticals Co. Ltd. have extended their collaboration past 2020 and encompasses an expanded range of innovative medical devices in the areas of cosmetic dermatology, plastic surgery, burns, wounds and scar management as well as preferential rights to Stratpharma’s new products under development.
In February 2013 Luqa launched Stratpharma’s scar therapy gel, STRATADERM®, a novel silicone gel formulation for the treatment of scars in China.
Under the extended collaboration agreement, Luqa Pharmaceuticals will register and commercialize Stratpharma’s innovative pipeline in China, rolling out four new products over the next three years.
“We are delighted with the progress of our collaboration with Stratpharma following the successful launch of STRATADERM® in China. Over the last years, Stratpharma and Luqa have formed a strong and close working relationship. We are excited to extend our collaboration to develop and commercialize innovative new treatments in order to further our contribution to enhance the quality of life of China’s population,” said Robert Braithwaite, CEO of Luqa Pharmaceuticals.
According to the International Survey on Aesthetic/Cosmetic Procedures performed in 2011, China is the world’s fastest growing market and the third largest in number of aesthetic procedures. Global data indicates that the wound management market is forecasted to rapidly grow, especially in the advanced wound market segments, from the current US$14 billion to US$21 billion by 2021.
——
Source: Luqa Pharmaceuticals.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
